Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the thirty-one ratings firms that are currently covering the firm, Marketbeat reports. Nine research analysts have rated the stock with a hold recommendation, twenty-one have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $904.41.
A number of research firms have commented on REGN. JPMorgan Chase & Co. lifted their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the company an "overweight" rating in a research note on Friday, October 30th. Raymond James Financial upped their target price on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an "outperform" rating in a report on Friday, July 31st. Canaccord Genuity Group increased their target price on shares of Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a "buy" rating in a research note on Wednesday, October 28th. Weiss Ratings upgraded shares of Regeneron Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a research note on Monday, November 2nd. Finally, Guggenheim raised their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the stock a "buy" rating in a report on Monday, November 2nd.
Check Out Our Latest Stock Report on Regeneron Pharmaceuticals
Insider Activity
In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 7,830 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the transaction, the director directly owned 5,219 shares in the company, valued at approximately $5,057,680.71. This trade represents a 60.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kathryn Guarini sold 400 shares of the business's stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $900.00, for a total value of $360,000.00. Following the completion of the transaction, the director directly owned 603 shares in the company, valued at approximately $542,700. The trade was a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 27,028 shares of company stock worth $25,025,950 over the last quarter. 6.97% of the stock is owned by insiders.
Institutional Investors Weigh In On Regeneron Pharmaceuticals
Several hedge funds have recently modified their holdings of the stock. Western Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth $26,000. Armstrong Advisory Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 466.7% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 28 shares during the period. Mowery & Schoenfeld Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $29,000. Trust Co. of Vermont purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $29,000. Finally, Fiduciary Financial Advisors purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $29,000. 83.31% of the stock is owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals News Roundup
Investors following REGN have been watching these news items:
- Positive Sentiment: The European Commission approved more flexible Libtayo dosing across its six approved cancer uses: a 700 mg dose every six weeks after initial treatment, and shorter infusion times in some cases. Greater convenience may support treatment adherence and the oncology franchise, although the direct revenue impact is uncertain. Regeneron announcement
- Positive Sentiment: Barclays raised its price target to $1,075 and maintained an Overweight rating, signaling a more favorable analyst view. Barclays rating information
- Neutral Sentiment: A preclinical milestone in Regeneron’s collaboration with CytomX triggered a $5 million payment to CytomX. It indicates program progress but is unlikely by itself to materially affect Regeneron’s financial outlook. CytomX announcement
Regeneron Pharmaceuticals Stock Performance
Shares of REGN opened at $945.53 on Thursday. The company's 50 day simple moving average is $824.37 and its 200-day simple moving average is $750.43. The firm has a market cap of $97.82 billion, a PE ratio of 20.88, a price-to-earnings-growth ratio of 1.27 and a beta of 0.10. Regeneron Pharmaceuticals has a 12-month low of $591.52 and a 12-month high of $991.73. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. Regeneron Pharmaceuticals's revenue for the quarter was up 36.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.83 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals will post 58.26 EPS for the current year.
Regeneron Pharmaceuticals Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.30%.
About Regeneron Pharmaceuticals
(
Get Free Report)
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company's medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.